Evaxion announces the success of its initial phase vaccine collaboration with MSD

Published: 21-Feb-2024

The conclusion of the antigen discovery and design phases marks a milestone for the development of the vaccine candidate, EVX-B3

Evaxion Biotech A/S, a clinical-stage TechBio company announces the successful completion of the initial phases of its vaccine collaboration with MSD.

The vaccine development project combines both organisations’ capabilities and know-how.

Using Evaxion's proprietary platform, AI-Immunology, Evaxion has identified novel vaccine targets against a bacterial pathogen causing severe health issues. 

Evaxion's CEO Christian Kanstrup states: "We are excited about the successful conclusion of the vaccine target discovery and design phases of the collaboration and are eagerly awaiting the next phase. We strongly believe that this collaboration will further validate the power of our AI-Immunology platform and contribute to improving lives by designing unique vaccines addressing serious medical conditions."

Tarit Mukhopadhyay, Vice President, Head of Infectious Diseases and Vaccine Discovery at MSD Research Laboratories, said: "At MSD, we are exploring new ways to apply AI technologies across the discovery-development continuum. We are excited to further advance our work with the Evaxion team."



You may also like